Breaking News Instant updates and real-time market news.

ACAD

ACADIA

$30.71

-1.1 (-3.46%)

07:30
10/04/16
10/04
07:30
10/04/16
07:30

ACADIA reinstated with a Market Perform at Leerink

Leerink analyst Paul Matteis resumed coverage of ACADIA with a Market Perform rating and $34 price target.

ACAD ACADIA
$30.71

-1.1 (-3.46%)

06/22/16
06/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Perform from Outperform at Oppenheimer with analysts led by Colin Rusch saying they do not view the acquisition of Solar City (SCTY) as the best use of Tesla's capital and human resources given the potential returns on capital possible in the electric industry versus the potential leverage in Tesla's auto platform. 2. SolarCity downgraded to Hold from Buy at Stifel with analyst Sven Eenmaa saying the risk/reward looks balanced in the wake of Tesla's bid. 3. AMC Networks (AMCX) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Ryan Fiftal saying 2016 new show launches have missed expectations, making it unlikely the company can grow EBITDA beyond 2016 as declining Walking Dead ratings pressure the top-line. 4. ACADIA (ACAD) downgraded to Neutral from Buy at BofA/Merrill with the firm citing valuation. 5. McDonald's (MCD), Wendy's (WEN), Papa John's (PZZA) and Domino's Pizza (DPZ) downgraded to Neutral from Buy at Nomura. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/24/16
06/24/16
NO CHANGE

Needham sees Brexit making EU drug reviews 'less efficient, more expensive'
Needham analyst including Alan Carr, Chad Messer, Danielle Brill and Esther Pang noted that if Article 50 is invoked following the Brexit vote, the European Medicines Agency will need to move out of its current base in London and the U.K. will need to create its own separate regulatory organization for drugs, concluding that Brexit will lead to a "less efficient, more expensive, and potentially lengthier regulatory process" for drug approval in the EU and the U.K. Among the companies that are currently in discussions with the EMA or have drugs under MAA review, Needham lists ACADIA (ACAD) Celator (CPXX), Cempra (CEMP), Gilead (GILD) Intercept (ICPT), Seattle Genetics (SGEN), Valeant (VRX) and Progenics (PGNX).
07/08/16
PIPR
07/08/16
NO CHANGE
Target $44
PIPR
Overweight
Piper reiterates Overweight on ACADIA following physician survey
Piper Jaffray analyst Charles Duncan says his firm's recent survey of U.S. neurologists and psychiatrists who treat Parkinson's disease patients provides further support for his "non-consensus" revenue build for ACADIA's Nuplazid in Parkinson's disease psychosis. Sentiment for the drug is positive, and doctors see value in treating PDP, Duncan tells investors in a research note. He reiterates an Overweight rating on ACADIA with a $44 price target.
08/05/16
AGIS
08/05/16
DOWNGRADE
Target $41
AGIS
Hold
ACADIA downgraded to Hold from Buy at Aegis
Aegis analyst Robert Leboyer downgraded ACADIA Pharmaceuticals to Hold with a $41 price target saying the stock at current levels is fairly valued.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.